1 |
Townsley DM, Scheinberg P, Winkler T, et al. Eltrombopag added to standard immunosuppression for aplastic anemia[J]. N Engl J Med, 2017, 376 (16): 1540-1550.
|
2 |
中华医学会血液学分会红细胞疾病(贫血)学组.再生障碍性贫血诊断与治疗中国专家共识(2017年版)[J].中华血液学杂志,2017,38(1):1-5.
|
3 |
Killick SB, Bown N, Cavenagh J, et al. Guidelines for the diagnosis and management of adult aplastic anaemia[J]. Br J Haematol, 2016, 172 (2): 187-207.
|
4 |
Huang YQ, Gou R, Diao YS, et al. Charlson comorbidity index helps predict the risk of mortality forpatients with type 2 diabetic nephropathy[J]. J Zhejiang Univ Sci B, 2014, 15 (1): 58-66.
|
5 |
Yang CC, Chen PC, Hsu CW, et al. Validity of the age-adjusted charlson comorbidity index on clinical outcomes for patients with nasopharyngeal cancer post radiation treatment: a 5-year nationwide cohort study[J]. PLoS One, 2015, 10 (1): e0117323.
|
6 |
沈悌,赵永强.血液病诊断及疗效标准[M]. 4版.北京:科学出版社,2018.
|
7 |
陈涛,肖溶,杨建和,等.骨髓增生异常综合征预后因素分析[J].临床血液学杂志,2011,24(4):400-403.
|
8 |
边士淇,寿松涛,李望等.查尔森合并症指数对脓毒症患者预后的评估价值[J].中国全科医学,2015,18(14):1637-1640.
|
9 |
王涛,顾永辉,崔云亮等.应用查尔森基础疾病权重指数评估脓毒症患者预后[J].第二军医大学学报,2013,34(7):750-753.
|
10 |
张霖,皮春梅,聂秀红.查尔森合并症指数对老年慢性阻塞性肺疾病患者预后的评估价值[J].中国呼吸与危重监护杂志,2016,15(4):333-336.
|
11 |
张定峰,左祥荣,曹权.慢性阻塞性肺疾病急性加重期患者急性胃肠损伤发生率及其预后研究[J/CD].中华危重症医学杂志(电子版),2016,9(5):334-338.
|
12 |
陶晓虹,董红华.再生障碍性贫血患者医院感染相关因素分析与预防[J].中华医院感染学杂志,2016,26(5):1020-1021,1030.
|
13 |
Zhu XF, He HL, Wang SQ, et al. Current treatment patterns of aplastic anemia in China: a prospective cohort registry study[J]. Acta Haematol, 2019, 142 (3): 162-170.
|
14 |
Bacigalupo A, Oneto R, Schrezenmeier H, et al. First line treatment of aplastic anemia with thymoglobuline in Europe and Asia: outcome of 955 patients treated 2001-2012[J]. Am J Hematol, 2019, 94 (1): 165.
|